Should I buy or sell Cabaletta Bio stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cabaletta Bio in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CABA shares. View CABA analyst ratings or view top-rated stocks .

What is Cabaletta Bio's stock price target for 2024?

9 equities research analysts have issued 12-month price targets for Cabaletta Bio's shares. Their CABA share price targets range from $25.00 to $50.00. On average, they expect the company's share price to reach $34.33 in the next year. This suggests a possible upside of 157.4% from the stock's current price. View analysts price targets for CABA or view top-rated stocks among Wall Street analysts .

How have CABA shares performed in 2024?

Cabaletta Bio's stock was trading at $22.70 at the beginning of the year. Since then, CABA stock has decreased by 41.2% and is now trading at $13.34. View the best growth stocks for 2024 here .

Are investors shorting Cabaletta Bio?

Cabaletta Bio saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 8,500,000 shares, an increase of 19.9% from the March 15th total of 7,090,000 shares. Based on an average trading volume of 946,600 shares, the short-interest ratio is currently 9.0 days. View Cabaletta Bio's Short Interest .

When is Cabaletta Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CABA earnings forecast .

How were Cabaletta Bio's earnings last quarter?

Cabaletta Bio, Inc. (NASDAQ:CABA) released its quarterly earnings results on Thursday, March, 21st. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.39) by $0.07.

What ETFs hold Cabaletta Bio's stock?

ETFs with the largest weight of Cabaletta Bio (NASDAQ:CABA) stock in their portfolio include Alger Mid Cap 40 ETF (FRTY) . Alger 35 ETF (ATFV) .

What other stocks do shareholders of Cabaletta Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cabaletta Bio investors own include Alector (ALEC) , Editas Medicine (EDIT) , Kaleido Biosciences (KLDO) , Sorrento Therapeutics (SRNE) , Homology Medicines (FIXX) , Skyworks Solutions (SWKS) , CrowdStrike (CRWD) , Precision BioSciences (DTIL) , Invitae (NVTA) and Pfizer (PFE) .

When did Cabaletta Bio IPO?

Cabaletta Bio (CABA) raised $87 million in an initial public offering on Friday, October 25th 2019. The company issued 5,800,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group served as the underwriters for the IPO.

Who are Cabaletta Bio's major shareholders?

Cabaletta Bio's stock is owned by a variety of institutional and retail investors. Top institutional investors include CHURCHILL MANAGEMENT Corp (0.10%). Insiders that own company stock include Anup Marda, Catherine Bollard, Gwendolyn Binder, Steven Nichtberger and Ventures V LP 5Am. View institutional ownership trends .

How do I buy shares of Cabaletta Bio?

Shares of CABA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CABA

Cabaletta Bio (CABA) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free CABA Stock Alerts

$13.34

-0.63 (-4.51%)

(As of 04/19/2024 ET)

Compare

Today's Range: $13.08
▼
$14.28
50-Day Range: $13.34
▼
$25.00
52-Week Range: $7.69
▼
$26.35

Volume: 1.18 million shs
Average Volume: 942,848 shs
Market Capitalization: $643.52 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $34.33

Get Cabaletta Bio alerts:

Cabaletta Bio MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 157.4% Upside
$34.33 Price Target
Short Interest: Bearish
17.62% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.71
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.82) to ($2.10) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.16 out of 5 stars

Medical Sector

470th out of 911 stocks

Biological Products, Except Diagnostic Industry

70th out of 150 stocks

4.5

Analyst's Opinion

Consensus Rating
Cabaletta Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Cabaletta Bio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
17.62% of the outstanding shares of Cabaletta Bio have been sold short.
Short Interest Ratio / Days to Cover
Cabaletta Bio has a short interest ratio ("days to cover") of 9.
Change versus previous month
Short interest in Cabaletta Bio has recently increased by 19.89%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Cabaletta Bio does not currently pay a dividend.
Dividend Growth
Cabaletta Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CABA.

3.2

News and Social Media Coverage

News Sentiment
Cabaletta Bio has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Cabaletta Bio this week, compared to 2 articles on an average week.
Search Interest
40 people have searched for CABA on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added Cabaletta Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cabaletta Bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
12.33% of the stock of Cabaletta Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Cabaletta Bio are expected to decrease in the coming year, from ($1.82) to ($2.10) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cabaletta Bio is -8.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cabaletta Bio is -8.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cabaletta Bio has a P/B Ratio of 2.42. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Cabaletta Bio Stock (NASDAQ:CABA)

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

CABA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CABA Stock News Headlines

April 18, 2024 | msn.com

Philly-area biotech is worried about Congress’ crackdown on Chinese manufacturers

April 18, 2024 | americanbankingnews.com

Cabaletta Bio, Inc. (NASDAQ:CABA) Given Average Rating of "Buy" by Analysts

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 17, 2024 | msn.com

🛠️ One Philly rowhouse at a time | Morning Newsletter

March 23, 2024 | investing.com

Stifel lifts Cabaletta Bio target to $32 on myositis position

March 23, 2024 | finance.yahoo.com

Cabaletta Bio Inc (CABA) Earnings: Aligns with EPS Projections, Forecasts Extended Cash Runway

March 22, 2024 | markets.businessinsider.com

Strong Buy on Cabaletta Bio: Promising CAR T Candidate and Robust Financial Outlook

March 21, 2024 | markets.businessinsider.com

Cabaletta Bio Earns ‘Buy’ Rating on Impressive Clinical Progress and Strategic Market Positioning

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 21, 2024 | investorplace.com

CABA Stock Earnings: Cabaletta Bio Misses EPS for Q4 2023

March 21, 2024 | msn.com

Cabaletta gets FDA orphan drug status for systemic sclerosis drug

March 21, 2024 | finance.yahoo.com

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 21, 2024 | globenewswire.com

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 20, 2024 | markets.businessinsider.com

Cabaletta Bio Says FDA Grants Orphan Drug Designation To CABA-201 To Treat Systemic Sclerosis

March 20, 2024 | finance.yahoo.com

Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis

March 19, 2024 | msn.com

A major cog in Philly biotech is in congressional crosshairs for its Chinese ownership

March 5, 2024 | msn.com

Cabaletta Bio Set to Ignite Conversation at Upcoming Health Care Conferences

February 27, 2024 | finance.yahoo.com

Several Factors Led to the Outperformance of Cabaletta Bio (CABA) in Q4

February 27, 2024 | globenewswire.com

Cabaletta Bio to Participate in Upcoming Investor Conferences in March

February 21, 2024 | benzinga.com

Cabaletta Bio Stock (NASDAQ:CABA) Dividends: History, Yield and Dates

February 17, 2024 | finance.yahoo.com

CABA Mar 2024 35.000 call

February 17, 2024 | finance.yahoo.com

CABA Mar 2024 30.000 call

February 5, 2024 | markets.businessinsider.com

Strong Buy Rating for Cabaletta Bio Amid Positive CART Therapy Prospects and Market Potential

February 3, 2024 | msn.com

FDA Awards Orphan Drug Designation to Cabaletta's Innovative Myositis Therapy

February 2, 2024 | msn.com

Cabaletta Bio CEO to Speak at Guggenheim's 6th Annual Biotech Conference

February 1, 2024 | marketwatch.com

Cabaletta Bio Gets Orphan Drug Designation for Potential Autoimmune Disease Treatment

January 31, 2024 | seekingalpha.com

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

See More Headlines

Receive CABA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cabaletta Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:CABA
CUSIP: N/A
CIK: 1759138
Web: www.cabalettabio.com
Phone: 267-759-3100
Fax: N/A
Employees: 101
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $34.33
High Stock Price Target: $50.00
Low Stock Price Target: $25.00
Potential Upside/Downside: +157.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.65)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-67,680,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -40.83%
Return on Assets: -37.86%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 15.29
Quick Ratio: 15.29

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.51 per share
Price / Book: 2.42

Miscellaneous

Outstanding Shares: 48,240,000
Free Float: 42,294,000
Market Cap: $643.52 million
Optionable: Optionable
Beta: 2.41

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Dr. Steven A. Nichtberger M.D. (Age 63)
Co-Founder, Chairman, CEO & President
Comp: $970.6k
Dr. Gwendolyn K. Binder Ph.D. (Age 49)
President of Science & Technology
Comp: $692.99k
Dr. David J. Chang FACR (Age 60)
M.D., M.P.H., Chief Medical Officer
Comp: $676.74k
Dr. Michael C. Milone M.D.
Ph.D., Co-Founder & Co-Chair of Scientific Advisory Board
Dr. Aimee Payne M.D.
Ph.D., Co-Founder & Co-Chair of Scientific Advisory Board
Mr. Anup Marda M.B.A. (Age 46)
Chief Financial Officer
Comp: $548.2k
Dr. Samik Basu M.D.
Chief Scientific Officer
Mr. Michael Gerard J.D. (Age 44)
General Counsel & Secretary
Ms. Heather Harte-Hall M.Sc.
Chief Compliance Officer
Ms. Martha O'Connor
Chief Human Resources Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CABA Stock Analysis - Frequently Asked Questions

Should I buy or sell Cabaletta Bio stock right now?: 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cabaletta Bio in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CABA shares.
View CABA analyst ratings or view top-rated stocks.
What is Cabaletta Bio's stock price target for 2024?: 9 equities research analysts have issued 12-month price targets for Cabaletta Bio's shares. Their CABA share price targets range from $25.00 to $50.00. On average, they expect the company's share price to reach $34.33 in the next year. This suggests a possible upside of 157.4% from the stock's current price.
View analysts price targets for CABA or view top-rated stocks among Wall Street analysts.
How have CABA shares performed in 2024?: Cabaletta Bio's stock was trading at $22.70 at the beginning of the year. Since then, CABA stock has decreased by 41.2% and is now trading at $13.34.
View the best growth stocks for 2024 here.
Are investors shorting Cabaletta Bio?: Cabaletta Bio saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 8,500,000 shares, an increase of 19.9% from the March 15th total of 7,090,000 shares. Based on an average trading volume of 946,600 shares, the short-interest ratio is currently 9.0 days.
View Cabaletta Bio's Short Interest.
When is Cabaletta Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our CABA earnings forecast.
How were Cabaletta Bio's earnings last quarter?: Cabaletta Bio, Inc. (NASDAQ:CABA) released its quarterly earnings results on Thursday, March, 21st. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.39) by $0.07.

What ETFs hold Cabaletta Bio's stock?: ETFs with the largest weight of Cabaletta Bio (NASDAQ:CABA) stock in their portfolio include Alger Mid Cap 40 ETF (FRTY).Alger 35 ETF (ATFV).
What other stocks do shareholders of Cabaletta Bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cabaletta Bio investors own include Alector (ALEC), Editas Medicine (EDIT), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Homology Medicines (FIXX), Skyworks Solutions (SWKS), CrowdStrike (CRWD), Precision BioSciences (DTIL), Invitae (NVTA) and Pfizer (PFE).
When did Cabaletta Bio IPO?: Cabaletta Bio (CABA) raised $87 million in an initial public offering on Friday, October 25th 2019. The company issued 5,800,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group served as the underwriters for the IPO.
Who are Cabaletta Bio's major shareholders?: Cabaletta Bio's stock is owned by a variety of institutional and retail investors. Top institutional investors include CHURCHILL MANAGEMENT Corp (0.10%). Insiders that own company stock include Anup Marda, Catherine Bollard, Gwendolyn Binder, Steven Nichtberger and Ventures V LP 5Am.
View institutional ownership trends.
How do I buy shares of Cabaletta Bio?: Shares of CABA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CABA) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Cabaletta Bio (CABA) Stock Price, News & Analysis

Cabaletta Bio MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Cabaletta Bio Stock (NASDAQ:CABA)

CABA Stock Price History

CABA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CABA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™